Is It Time To Consider Buying Retail Food Group Limited (ASX:RFG)?
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Is Retail Food Group Still Cheap?
Great news for investors – Retail Food Group is still trading at a fairly cheap price according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 14.42x is currently well-below the industry average of 32.96x, meaning that it is trading at a cheaper price relative to its peers. However, given that Retail Food Group's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.
Check out our latest analysis for Retail Food Group
What kind of growth will Retail Food Group generate?
Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Retail Food Group's earnings over the next few years are expected to increase by 37%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.
What This Means For You
Are you a shareholder? Since RFG is currently trading below the industry PE ratio, it may be a great time to increase your holdings in the stock. With an optimistic profit outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current price multiple.
Are you a potential investor? If you've been keeping an eye on RFG for a while, now might be the time to make a leap. Its buoyant future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy RFG. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment.
So while earnings quality is important, it's equally important to consider the risks facing Retail Food Group at this point in time. Case in point: We've spotted 2 warning signs for Retail Food Group you should be aware of.
If you are no longer interested in Retail Food Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Hansen secures a significant three-year contract extension with Africa's MultiChoice Group
MultiChoice will upgrade to the latest version of Hansen CCB and extend its managed services solutions agreement as it continues to navigate Africa's complex and diverse regional and country regulations. MELBOURNE, Australia, July 29, 2025--(BUSINESS WIRE)--Hansen Technologies (ASX:HSN), a leading global provider of software and services to the communications & media and energy & utilities industries, has signed a three-year contract renewal with MultiChoice Group to enable the continued utilisation of Hansen CCB, as well as the extension of the existing managed services solutions. The agreement, initially for a term of three years, combines various contracts into a single master contract; aligning to MultiChoice's ambition to transition to this latest version of Hansen CCB. MultiChoice is a South African company that operates DStv, a major satellite television service in Sub-Saharan Africa. As Africa's leading entertainment platform, MultiChoice offers a diverse range of content across multiple brands and countries. For over 25 years, MultiChoice has relied on Hansen for their single billing solution, which supports subscribers across 50 markets. Hansen's continued investment into the CCB platform has allowed MultiChoice to adeptly and efficiently handle the mission critical complexities of the various regional requirements and diverse country regulations across Africa. The extension of the contract is a reflection of MultiChoice's resounding confidence in Hansen, not only as a platform provider but as a partner in their evolving future. MultiChoice Group Chief Technology & Information Officer, Sabelo Mwali comments: "Hansen has proven to be an invaluable partner over many years, consistently providing software and services that have resulted in a highly flexible, reliable and efficient billing platform for the MultiChoice Group. "We look forward to continuing and expanding our highly successful collaboration with Hansen for many years to come." Hansen's President of Communications & Media, Scott Weir, shares: "This agreement re-iterates the confidence Tier-1 industry players hold in Hansen's technology and expertise to deliver mission-critical Billing solutions. "We look forward to the further extension of the long-standing relationship we have built over the years as we continue to support MultiChoice's ambitions of further innovation and investment into the entertainment arena in Africa." For further information about Hansen, please visit About Hansen Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy & utilities and communications & media industries. With its award-winning software portfolio, Hansen serves organisations with customers located in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes. For more information, visit About MultiChoice MultiChoice is Africa's leading entertainment platform, with a mission to enrich lives. The company offers a wide range of products and services, including DStv, GOtv, Showmax, M-Net, SuperSport, Irdeto, and KingMakers. Its products and services are used by over 23.5 million households in 50 markets across sub-Saharan Africa. View source version on Contacts For further information, please contact: Megan RosierDirector, Corporate Communications & Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from 6-9 September 2025. The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company's antigen presenting cell (APC) activator, eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC). The global trial will enrol approximately 750 patients regardless of PD-L1 expression (Tumour Proportion Score or TPS of 0-100%) and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries. Immutep CMO, Stephan Winckels M.D., Ph.D, said, 'Our engagement to date with physicians in the lung cancer community, including at ELCC in Paris and ASCO in Chicago, has yielded encouraging feedback with a shared view of efti as a safe, easy-to-administer immunotherapy with strong efficacy across two 1L NSCLC trials. We look forward to continuing our investigator discussions at WCLC and ESMO around the pivotal TACTI-004 Phase III, which has the potential to change the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer, irrespective of their PD-L1 expression.' Details for the poster presentation:Title: TACTI-004, a Phase 3 trial of Eftilagimod Alfa plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1st line NSCLC Presenter: Dr. Martin Sebastian, University Hospital of Frankfurt, GermanySession: Clinical Trials in ProgressDate and Time: Tuesday, 9 September 2025 at 10:00 AM CEST The poster will be available on the Posters & Publications section of Immutep's website following the presentation. About Eftilagimod Alfa (efti)Efti is Immutep's proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a first-in-class antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system's ability to fight is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; in to access your portfolio
Yahoo
5 hours ago
- Yahoo
CBA cuts jobs amid AI chatbot rollout
The Commonwealth Bank of Australia (CBA) has announced the termination of 45 positions within its call centres following the introduction of an AI chatbot designed to handle customer inquiries. The bank has communicated to the impacted employees that consultations are ongoing regarding the job cuts, according to Australian Broadcasting Corporation (ABC). CBA announced it is investing more than A$2bn ($1.30bn) in its operations, including frontline teams and technology services, which may result in "some roles and work can change," reported Reuters. The Finance Sector Union (FSU) has expressed discontent with the decision, advocating for the retraining of affected workers to transition into new roles that utilise AI technology. The CBA stated that it has recruited more than 9,000 individuals in the past year and currently has approximately 670 vacancies within its retail banking services and frontline teams. CBA spokesperson was quoted by ABC as saying: 'To meet the changing needs of our customers, like many organisations, we review the skills we need and how we're organised to deliver the best customer experiences and outcomes. That means some roles and work can change 'Our priority is to explore opportunities for redeployment and to support affected employees with care, dignity and respect throughout the process.' Last week, the CBA informed the FSU about the job reductions, marking a significant moment as it is reportedly the first instance where a bank has attributed job cuts directly to AI implementation. The bank has dismissed claims that these job losses are linked to offshoring, asserting that it plans to provide reskilling opportunities for those affected. A report from CSIRO indicates that 68% of Australian businesses have adopted AI technologies, leading to a notable shift in customer service roles, with many being replaced by chatbots and virtual assistants. "CBA cuts jobs amid AI chatbot rollout" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data